Physician profile
Gary Czulada
NPI 1477578573
$14,845.36
in general payments reported to CMS, 2019-2025
55 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,353 · 2020: $1,788 · 2021: $2,291 · 2022: $2,255 · 2023: $2,114 · 2024: $1,965 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,158.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,231.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,436.15 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,430.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,199.55 | 2019-2025 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $1,064.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,025.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $948.33 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Janssen Pharmaceuticals, INC | $530.59 | 2019-2025 | Xarelto, Spravato |
| Amarin Pharma, INC. | $528.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $509.84 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $325.97 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $253.38 | 2019-2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.81 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $221.53 | 2019-2025 | Evenity |
| Sanofi Pasteur INC. | $216.38 | 2019-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Czulada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.